For the roughly one in 10,000 to 20,000 adults living with osteogenesis imperfecta (OI), fracture risk is a lifelong burden with few evidence-based treatment options beyond supportive care. This trial directly tests whether combining two established bone-modifying agents — one anabolic, one antiresorptive — can meaningfully shift that equation, potentially redefining standard of care for a condition historically managed with bisphosphonate monotherapy alone.
This randomized clinical trial, published in JAMA, evaluated whether adding zoledronic acid — an intravenous bisphosphonate that suppresses osteoclast-mediated bone resorption — to teriparatide, a synthetic parathyroid hormone fragment that stimulates new bone formation, would reduce fracture incidence in adults with OI compared to conventional treatment. The combination targets OI's dual pathology: impaired collagen matrix quality alongside dysregulated bone turnover. By pairing an anabolic agent with an antiresorptive, the protocol attempts to simultaneously build bone volume and slow its destruction — a strategy that has shown benefit in severe postmenopausal osteoporosis.
The finding is notable for several reasons. OI is a rare disease, meaning randomized trials are exceptionally difficult to power adequately, and this study's design deserves scrutiny regarding cohort size and follow-up duration. Adult OI differs meaningfully from pediatric presentations — growth plate dynamics no longer apply, but cumulative skeletal fragility and atypical fracture patterns remain prominent. Teriparatide carries a historical boxed warning regarding osteosarcoma risk from rodent studies, which adds a layer of clinical consideration in a population already managing a genetic connective tissue disorder. The broader implication is significant: if combination therapy demonstrates superior fracture reduction over bisphosphonate monotherapy, it could establish a new benchmark not only for OI management but also for thinking about sequential versus concurrent bone-anabolic strategies in other high-fracture-risk populations. This trial should be considered potentially practice-changing, contingent on effect size and safety profile from the full dataset.